Is Fennec Pharmaceuticals Inc. (FENC) a Buy, Sell, or Hold?
NASDAQ : FENC
Fennec Pharmaceuticals Inc. — Institutional Ownership
$11.575 USD
$0.73 (6.78%)
- Volume
- 224.81K
- Average Volume
- 265.12K
- Market Capitalization
- $402.08M
- P/E Ratio
- -37.69
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $11.66
- Year Low
- $5.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.98
Institutional Ownership Summary
Institutional Ownership %
14.82%
Investors Holding
33
change: -58.0 | last: 91
Increased Positions
19
change: -36.0 | last: 55
Reduced Positions
4
change: -14.0 | last: 18
New Positions
4
change: -13.0 | last: 17
Sold Positions
62
change: 40.0 | last: 22
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: 0.0 | last: 0
Total Invested
54.45M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-15 | Solas Capital Management, LLC | 2.48M | 7.20% |
| 2026-05-14 | Rosalind Advisors, Inc. | 3.04M | 8.80% |
| 2026-04-28 | Orin Hirschman | 1.98M | 5.70% |
| 2026-02-17 | Sonic Fund II, L.P. | 2.61M | 7.60% |
| 2026-02-11 | Rosalind Advisors, Inc. | 2.75M | 9.80% |
| 2026-01-14 | Southpoint Master Fund, LP | 2.74M | 8.00% |
| 2025-11-13 | Rosalind Advisors, Inc. | 2.08M | 7.50% |
| 2025-02-14 | Solas Capital Management, LLC | 2.25M | 8.20% |
| 2025-02-14 | DG Capital Management, LLC | 1.11M | 4.10% |
| 2024-06-27 | DG Capital Management, LLC | 1.42M | 5.20% |
| 2024-06-27 | DG Value Partners II Master Fund, LP | 1.42M | 5.20% |
| 2024-06-27 | Dov Gertzulin | 1.42M | 5.20% |
| 2024-02-14 | 2. | 1.38M | 5.20% |
| 2022-02-14 | LAWRENCE KAM | 2.47M | 9.50% |
| 2022-02-14 | THE SONIC FUND II, L.P. | 2.41M | 9.30% |
| 2022-02-11 | Avoro Capital Advisors LLC | 1.2M | 4.60% |
| 2022-02-11 | Behzad Aghazadeh | 1.2M | 4.60% |
| 2021-02-12 | LLC | 4.08M | 15.80% |
| 2021-02-12 | Advisors LP | 4.08M | 15.80% |
| 2021-02-12 | LP | 4.08M | 15.80% |
| 2021-02-12 | II | 4.08M | 15.80% |
| 2021-02-12 | Fund, LP | 4.08M | 15.80% |
| 2021-02-12 | Advisors LLC | 4.08M | 15.80% |
| 2019-02-14 | Ari Zweiman | 971.35K | 4.90% |
| 2019-02-14 | 683 Capital Partners, LP | 971.35K | 4.90% |
| 2019-02-14 | 683 Capital Management, LLC | 971.35K | 4.90% |
| 2018-06-22 | Opaleye Management Inc. | 9.0 | 11.00% |
| 2018-06-22 | 1 | 9.0 | 11.00% |
| 2018-06-22 | 1 | 9.0 | 11.00% |
| 2018-02-14 | 2 | 4M | 21.90% |
| 2018-02-12 | Behzad Aghazadeh | 1.11M | 6.10% |
| 2018-02-12 | venBio Select Advisor LLC | 1.11M | 6.10% |
| 2017-12-19 | Enrico Cavazza | 3.23M | 17.70% |
| 2017-12-19 | Silvia Cavazza | 3.23M | 17.70% |
| 2017-12-19 | Martina Cavazza Preta | 3.23M | 17.70% |
| 2017-12-19 | Essetifin S.p.A. | 3.23M | 17.70% |
| 2017-12-19 | Paolo Cavazza | 3.23M | 17.70% |
| 2017-12-19 | Francesca Cavazza | 3.23M | 17.70% |
| 2017-02-14 | 683 Capital Management, LLC | 787.53K | 5.70% |
| 2017-02-14 | Ari Zweiman | 787.53K | 5.70% |
| 2017-02-14 | 683 Capital Partners, LP | 787.53K | 5.70% |
| 2015-01-28 | 683 Capital Partners, LP | 932.9K | 8.70% |
| 2015-01-28 | 683 Capital Management, LLC | 932.9K | 8.70% |
| 2015-01-28 | Ari Zweiman | 932.9K | 8.70% |
| 2011-04-27 | 683 Capital Management, LLC | 38.92M | 8.60% |
| 2011-04-27 | 683 Capital Partners, LP | 38.92M | 8.60% |
| 2011-04-27 | Ari Zweiman | 38.92M | 8.60% |
| 2007-03-02 | 20-1158521 | 62.26M | 42.40% |
| 2007-03-02 | 20-0975910 | 62.26M | 42.40% |
| 2007-03-02 | Southpoint Offshore Fund, Ltd. | 62.26M | 42.40% |
| 2007-03-02 | 20-1095583 | 62.26M | 42.40% |
| 2007-03-02 | 20-1095649 | 62.26M | 42.40% |
| 2007-03-02 | John S. Clark II | 62.26M | 42.40% |
| 2007-03-02 | 20-1064783 | 62.26M | 42.40% |
| 2007-03-02 | 20-0975900 | 62.26M | 42.40% |
| 2007-03-02 | 20-1095514 | 62.26M | 42.40% |
| 2007-03-02 | Robert W. Butts | 62.26M | 42.40% |
| 2006-02-10 | GlaxoSmithKline plc | 2.79M | 7.50% |
| 2005-07-13 | William P. Peters | 10.93M | 5.98% |
| 2005-02-14 | I.R.S. Identification Nos. of above persons (: | 100.0 | 10.90% |
FENC Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $7.70 | 28.58M | $220.04M | $36.72M | -$ | $183.32M |
| 2024-12-31 | $6.32 | 27.29M | $172.5M | $26.63M | $19.34M | $165.2M |
| 2023-12-31 | $11.22 | 26.57M | $298.16M | $13.27M | $30.95M | $315.85M |
| 2022-12-31 | $9.60 | 26.28M | $252.24M | $23.77M | $24.9M | $253.36M |
| 2021-12-31 | $4.40 | 26.01M | $114.43M | $21.1M | $4.99M | $98.31M |
| 2020-12-31 | $7.45 | 23.7M | $176.59M | $30.34M | -$ | $146.25M |
| 2019-12-31 | $6.49 | 19.9M | $129.13M | $13.65M | -$ | $115.48M |
| 2018-12-31 | $6.38 | 18.94M | $120.85M | $22.78M | -$ | $98.07M |
| 2017-12-31 | $10.02 | 14.99M | $150.21M | $28.26M | -$ | $121.95M |
| 2016-12-31 | $12.00 | 12.68M | $152.13M | $3.93M | -$ | $148.2M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6.15 | 34.34M | $211.17M | $40.18M | -$ | $170.99M |
| 2025-12-31 | $7.70 | 31.18M | $240.05M | $36.79M | -$ | $203.26M |
| 2025-09-30 | $9.36 | 27.89M | $261.04M | $21.95M | $19.38M | $258.47M |
| 2025-06-30 | $8.30 | 27.66M | $229.61M | $18.7M | $19.36M | $230.27M |
| 2025-03-31 | $6.09 | 27.58M | $167.95M | $22.68M | $19.35M | $164.63M |
| 2024-12-31 | $6.32 | 27.46M | $173.55M | $26.63M | $19.34M | $166.25M |
| 2024-09-30 | $5.00 | 27.37M | $136.86M | $40.32M | $32.1M | $128.64M |
| 2024-06-30 | $6.27 | 27.3M | $171.15M | $43.05M | $31.79M | $159.89M |
| 2024-03-31 | $10.84 | 27.04M | $293.17M | $51.18M | $31.37M | $273.35M |
| 2023-12-31 | $11.22 | 26.83M | $301.07M | $13.27M | $30.95M | $318.75M |
| 2023-09-30 | $7.51 | 26.46M | $198.7M | $12.4M | $25.67M | $211.97M |
| 2023-06-30 | $8.83 | 26.46M | $233.62M | $14.96M | $25.39M | $244.05M |